Biomerica Ev To Sales from 2010 to 2024

BMRA Stock  USD 0.39  0.07  21.88%   
Biomerica's EV To Sales is increasing over the years with slightly volatile fluctuation. Overall, EV To Sales is expected to go to 2.31 this year. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
1.17851296
Current Value
2.31
Quarterly Volatility
2.39603964
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biomerica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomerica's main balance sheet or income statement drivers, such as Depreciation And Amortization of 212 K, Interest Expense of 32.2 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 2.74, Dividend Yield of 0.0 or PTB Ratio of 2.3. Biomerica financial statements analysis is a perfect complement when working with Biomerica Valuation or Volatility modules.
  
Check out the analysis of Biomerica Correlation against competitors.
For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.

Latest Biomerica's Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Biomerica over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Biomerica's EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomerica's overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Biomerica Ev To Sales Regression Statistics

Arithmetic Mean2.72
Geometric Mean1.89
Coefficient Of Variation87.96
Mean Deviation1.86
Median2.01
Standard Deviation2.40
Sample Variance5.74
Range8.2166
R-Value0.37
Mean Square Error5.32
R-Squared0.14
Significance0.17
Slope0.20
Total Sum of Squares80.37

Biomerica Ev To Sales History

2024 2.31
2023 1.18
2022 2.01
2021 2.11
2020 5.69
2019 8.62
2018 3.85

About Biomerica Financial Statements

Biomerica stakeholders use historical fundamental indicators, such as Biomerica's Ev To Sales, to determine how well the company is positioned to perform in the future. Although Biomerica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biomerica's assets and liabilities are reflected in the revenues and expenses on Biomerica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biomerica. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Sales 1.18  2.31 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:
Check out the analysis of Biomerica Correlation against competitors.
For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
0.327
Quarterly Revenue Growth
0.055
Return On Assets
(0.39)
Return On Equity
(0.76)
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.